Latest Healthcare News

EBOS Group Limited reported a solid 13% increase in revenue for the first half of FY2026, alongside a 13% rise in net profit attributable to owners, while maintaining its interim dividend.

Thorney Technologies reported a sharply reduced half-year profit amid challenging market conditions but extended its share buyback to support shareholder value.

333D Limited reported a 23% increase in revenue to $588,678 for the half-year ended December 2025, despite a 92% plunge in profit after tax to a $282,030 loss. The company boosted its cash reserves significantly and initiated a strategic Bitcoin investment.

Firebrick Pharma reports a reduced half-year loss of $1.26 million while launching its Nasodine Throat Spray in Singapore and Fiji, with regulatory approval pending in the Philippines.

Tetratherix Limited reported a $4.6 million statutory loss for the first half of FY26, driven by increased R&D and manufacturing investments, while making significant progress in clinical trials and securing key global partnerships.

OncoSil Medical has reported record dose sales and cash receipts in the first half of FY26, supported by encouraging clinical trial results and expanded European market penetration.

Radiopharm Theranostics has initiated dosing in its Phase 1/2a clinical trial of BetaBart, a novel radiotherapeutic developed with MD Anderson Cancer Center, targeting aggressive solid tumors.

Orthocell Limited has reported a record half-year revenue of $6.2 million, driven by accelerating sales of its regenerative medicine products and expanding global footprint. The company’s US commercial launch of Remplir™ is gaining momentum alongside new market entries in Canada, Hong Kong, and Europe.

Singular Health Group reported a 55% rise in net loss to $2.97 million for H1 FY2026, driven by share-based payments and strategic hires, while making significant progress in US commercial deployments and securing FDA clearance for its cloud-based 3D medical imaging platform.

L1 Global Long Short Fund Limited reports a remarkable half-year turnaround with a 609% jump in net profit, driven by a new investment manager and a refreshed strategy. The company also declares a fully franked interim dividend as it completes a major equity raise and portfolio transition.

Lumos Diagnostics has hit a key enrollment milestone in its BARDA-funded paediatric study for FebriDx®, unlocking a US$720,000 payment and edging closer to FDA expansion.

JCurve Solutions has reported a strong half-year performance, returning to profitability with a 32% increase in revenue to $7.02 million, driven by higher NetSuite commissions and a strategic shift towards larger customers.